Oncology Biosimilar is the identical copy of oncology biologics used for the treatment of cancer. These drugs are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry.
According to the World Health Organization (WHO), in 2015, approximately 8.8 million people died due to cancer worldwide. Increasing prevalence of several types of cancers such as blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, and cervical cancer across the globe is supporting the market growth. Cancer is a disease characterized by uncontrolled growth and spread of abnormal cells in the body. Increasing risk of cancer is associated with increasing age. Approximately 77% of all cancers are diagnosed in elder population and most cases of cancer occur in middle-aged adults or older population.
About 40% of deaths occur from cancer in developing countries and in middle class population owing to unhealthy lifestyle. Furthermore, in 2018, lung, liver, stomach, colorectal and prostate cancers are five types of cancers that kill men more frequently as compared to other cancer types across the globe.
The global oncology biosimilar market accounted for over USD 2655 million in 2017 and is expected to grow at a CAGR of 23 % during the forecast period, 2019–2026.
To learn more about key trends >> Download Sample Report
The global oncology biosimilar market is segmented by types of cancer, drug type and distribution channel.
On the basis of types of cancer, oncology biosimilar market is segmented into breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, and others. Breast cancer is expected to be the leading segment during forecast period 2019–2026 due to increasing prevalence of breast cancer worldwide.
Based on drug type the market is segmented into mAb, immunomodulators, hematopoietic agents, G-CSF, and others. G-CSF is expected to hold major market share in the forecast period 2019–2026. Increasing demand of G-CSF is increasing due to high prevalence of breast cancer across the globe.
On the basis of the distribution channel, the market is segmented into retail pharmacies, hospital pharmacy, and online pharmacy. Hospital pharmacy is expected to hold major market share during the forecast period.
Geographically, the global oncology biosimilar market is segmented into North America, Europe, Asia-pacific, and LAMEA.
To understand geography trends >> Download Sample Report
North America is likely to hold the largest market share in the global oncology biosimilar market during the forecast period 2019–2026. According to the American Society of Cancer (ASC) during 2006—2015, approximately 1.8 million new cases of cancer were diagnosed and around 606,880 deaths from cancer are expected to occur in the US in 2019.
Europe oncology biosimilar market is expected to grow significantly. Increasing prevalence of breast cancer in the U.K and registration of over 55,000 breast cancer cases each year in the U.K and around 4,700 in Scotland are some of the factors expected to support the market growth in the region. Rise in the number of cases of breast cancer owing to adoption of unhealthy life style such less physically activity, increasing alcohol consumption, and obesity is fuelling the growth of the oncology biosimilar market. Similarly, approximately 350 men are diagnosed with cancer each year in the U.K which is escalating the market growth further.
Asia Pacific (APAC) is expected to be the fastest growing oncology biosimilar market during the forecast period 2019–2026. Breast cancer is widely spread in Asian countries owing to unhealthy lifestyle, increasing obesity which has increased demand of oncology biosimilar market. Furthermore, according to the World Health Organization (WHO) Cancer Report, in India, rising new cases of lung, oral, lip, throat and neck cancers are most common in men, while increasing prevalence of cervix, breast and ovarian cancers in women. Along with this, increasing prevalence of cancer such as kidney, intestine and prostate cancer in geriatric population in China due to rise in number of smoking population is influencing the market growth.
LAMEA is expected to grow at a steady rate owing to the undeveloped healthcare infrastructure. Lack of awareness about the healthy lifestyle is slowing the cancer treatment in this region. In the Middle East and Africa improving healthcare infrastructure and rising government initiatives in healthcare are the supporting factors of the market.
Some of the key players in oncology biosimilar market are Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD